Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
There is a lack of evidence for initiating renin-angiotensin system inhibitors (RASIs) in patients with nonproteinuric chronic kidney disease (CKD).
We enrolled a retrospective cohort of patients with chronic kidney disease and urinary albumin-to-creatinine ratio (ACR) of less than 30 mg/g from 28 medical centers across China. We emulated sequential target trials to evaluate the intent-to-treat effect of initiating RASIs on the all-cause and cardiovascular mortality The key elements of the target and emulated trials are summarized in Table 1. The Schematic illustration of emulated target trial design are showed in Figure1. The primary estimands were three-year risk differences between those with and without initiating the RASIs therapy. Additionally, we investigated the three-year risk difference of RASIs initiation on composite kidney outcomes defined as more than 25% decline in the estimated GFR with CKD stage deterioration or initiating kidney replacement therapy.
A total of 17,382 eligible person-trials (10,101 unique persons) were included. On enrollment, 2596 and 14,786 person-trials were assigned to the RASIs initiation group and the control group, respectively. The three-year cumulative incidence of all-cause mortality was 14.88% (95% confidence interval [CI], 13.65% to 16.51%) and 18.26% (95% CI, 17.67% to 19.42%) in the RASIs initiation group and the control group, respectively, with a risk difference of −3.39% (95% CI, −4.71% to −2.07%). The significant benefit of RASIs initiation was also observed in terms of cardiovascular mortality, with a three-year risk difference of -1.46% (95%CI, -2.57% to -0.52%) (Table2). The curves of the adjusted cumulative incidences stratified by the two treatment groups were presented in Figure 2. Estimates from the subgroup (Figure3) and the pre-protocol analyses(Table 3) were consistent with the primary analysis. Similar trend of association was observed for the treatment initiation on composite kidney outcomes, though the three-year cumulative risk difference between groups did not reach statistical significance (risk difference, −0.88%; 95% CI, −2.42% to 1.40%) (Table4).
Patients with nonproteinuric CKD may benefit from initiating RASIs for reducing risk of all-cause and cardiovascular mortality.
